Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Jul;103(3):1719–1724. doi: 10.1111/j.1476-5381.1991.tb09853.x

Prehispanolone, a novel platelet activating factor receptor antagonist from Leonurus heterophyllus.

C M Lee 1, L M Jiang 1, H S Shang 1, P M Hon 1, Y He 1, H N Wong 1
PMCID: PMC1907812  PMID: 1657264

Abstract

1. Using an in vitro radioligand binding assay for the platelet activating factor (PAF) receptor, we have identified a novel, specific PAF antagonist, prehispanolone, from a Chinese medicinal herb Leonurus heterophyllus. 2. The presence of sodium ions inhibited specific [3H]-PAF binding to rabbit platelet membrane with an IC50 of 5.2 mM, decreased the inhibitory potency of PAF but increased the inhibitory potency of prehispanolone. 3. Prehispanolone and several of its derivatives inhibited the binding of [3H]-PAF to rabbit platelets with potencies closely resembling that of inhibition of PAF-induced aggregation. 4. The integrity of the tetrahydrofuran ring of prehispanolone is critical for its interaction with the PAF receptor. 5. By hydrogenating the dihydrofuran ring and replacing the keto group of prehispanolone with a hydroxyl group, we obtained a compound, LC5507, that is more stable and more active than prehispanolone as a PAF receptor antagonist.

Full text

PDF
1719

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benveniste J., Henson P. M., Cochrane C. G. Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med. 1972 Dec 1;136(6):1356–1377. doi: 10.1084/jem.136.6.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Benveniste J., Tencé M., Varenne P., Bidault J., Boullet C., Polonsky J. Semi-synthèse et structure proposée du facteur activant les plaquettes (P.A.F.): PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine. C R Seances Acad Sci D. 1979 Nov 26;289(14):1037–1040. [PubMed] [Google Scholar]
  3. Blank M. L., Snyder F., Byers L. W., Brooks B., Muirhead E. E. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Commun. 1979 Oct 29;90(4):1194–1200. doi: 10.1016/0006-291x(79)91163-x. [DOI] [PubMed] [Google Scholar]
  4. Braquet P., Paubert-Braquet M., Koltai M., Bourgain R., Bussolino F., Hosford D. Is there a case for PAF antagonists in the treatment of ischemic states? Trends Pharmacol Sci. 1989 Jan;10(1):23–30. doi: 10.1016/0165-6147(89)90103-x. [DOI] [PubMed] [Google Scholar]
  5. Braquet P., Touqui L., Shen T. Y., Vargaftig B. B. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987 Jun;39(2):97–145. [PubMed] [Google Scholar]
  6. Demopoulos C. A., Pinckard R. N., Hanahan D. J. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979 Oct 10;254(19):9355–9358. [PubMed] [Google Scholar]
  7. Feuerstein G., Hallenbeck J. M. Prostaglandins, leukotrienes, and platelet-activating factor in shock. Annu Rev Pharmacol Toxicol. 1987;27:301–313. doi: 10.1146/annurev.pa.27.040187.001505. [DOI] [PubMed] [Google Scholar]
  8. Hwang S. B., Lam M. H., Chang M. N. Specific binding of [3H]dihydrokadsurenone to rabbit platelet membranes and its inhibition by the receptor agonists and antagonists of platelet-activating factor. J Biol Chem. 1986 Oct 15;261(29):13720–13726. [PubMed] [Google Scholar]
  9. Hwang S. B., Lam M. H., Pong S. S. Ionic and GTP regulation of binding of platelet-activating factor to receptors and platelet-activating factor-induced activation of GTPase in rabbit platelet membranes. J Biol Chem. 1986 Jan 15;261(2):532–537. [PubMed] [Google Scholar]
  10. Hwang S. B., Lam M. H., Shen T. Y. Specific binding sites for platelet activating factor in human lung tissues. Biochem Biophys Res Commun. 1985 Apr 30;128(2):972–979. doi: 10.1016/0006-291x(85)90142-1. [DOI] [PubMed] [Google Scholar]
  11. Hwang S. B., Lee C. S., Cheah M. J., Shen T. Y. Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes. Biochemistry. 1983 Sep 27;22(20):4756–4763. doi: 10.1021/bi00289a022. [DOI] [PubMed] [Google Scholar]
  12. Iñarrea P., Gomez-Cambronero J., Nieto M., Crespo M. S. Characteristics of the binding of platelet-activating factor to platelets of different animal species. Eur J Pharmacol. 1984 Oct 15;105(3-4):309–315. doi: 10.1016/0014-2999(84)90623-x. [DOI] [PubMed] [Google Scholar]
  13. Saunders R. N., Handley D. A. Platelet-activating factor antagonists. Annu Rev Pharmacol Toxicol. 1987;27:237–255. doi: 10.1146/annurev.pa.27.040187.001321. [DOI] [PubMed] [Google Scholar]
  14. Shi M. M., Wu J. S., Lee C. M., Young J. D. Nucleoside transport. Photoaffinity labelling of high-affinity nitrobenzylthioinosine binding sites in rat and guinea pig lung. Biochem Biophys Res Commun. 1984 Jan 30;118(2):594–600. doi: 10.1016/0006-291x(84)91344-5. [DOI] [PubMed] [Google Scholar]
  15. Tahraoui L., Floch A., Mondot S., Cavero I. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation. Mol Pharmacol. 1988 Aug;34(2):145–151. [PubMed] [Google Scholar]
  16. Valone F. H., Coles E., Reinhold V. R., Goetzl E. J. Specific binding of phospholipid platelet-activating factor by human platelets. J Immunol. 1982 Oct;129(4):1637–1641. [PubMed] [Google Scholar]
  17. Valone F. H., Goetzl E. J. Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. Immunology. 1983 Jan;48(1):141–149. [PMC free article] [PubMed] [Google Scholar]
  18. Valone F. H. Identification of platelet-activating factor receptors in P388D1 murine macrophages. J Immunol. 1988 Apr 1;140(7):2389–2394. [PubMed] [Google Scholar]
  19. Vargaftig B. B., Braquet P. G. PAF-acether today--relevance for acute experimental anaphylaxis. Br Med Bull. 1987 Apr;43(2):312–335. doi: 10.1093/oxfordjournals.bmb.a072185. [DOI] [PubMed] [Google Scholar]
  20. Wong D. T., Bymaster F. P., Reid L. R., Threlkeld P. G. Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol. 1983 Apr 1;32(7):1287–1293. doi: 10.1016/0006-2952(83)90284-8. [DOI] [PubMed] [Google Scholar]
  21. Zou Q. Z., Bi R. G., Li J. M., Feng J. B., Yu A. M., Chan H. P., Zhen M. X. Effect of motherwort on blood hyperviscosity. Am J Chin Med. 1989;17(1-2):65–70. doi: 10.1142/S0192415X89000115. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES